Ace Therapeutics, a preclinical stroke research services provider, is enhancing hemorrhagic stroke research through customized in vitro and in vivo models designed to replicate intracerebral hemorrhage (ICH) pathophysiology. The company's approach addresses the complex mechanisms of ICH, including hematoma expansion, neuronal cell death, oxidative stress, blood-brain barrier disruption, and neuroinflammation, which are critical barriers to developing effective treatments.
The company's in vitro models serve specific research purposes, from high-throughput screening to targeted pathway analysis. Hemoglobin models reflect hematoma expansion and enable studies on iron dynamics and hemoglobin proteolysis, while hemin models mimic secondary injury pathways like blood-brain barrier disruption and neuroinflammation. Autologous blood models replicate the full hemotoxicity of ICH, providing a physiologically relevant platform for studying blood-induced brain injury. These models allow researchers to isolate and analyze targeted mechanisms without confounding variables, as detailed in their in vitro ICH models portfolio.
For translational research, Ace Therapeutics offers comprehensive animal models through its ICH animal model CRO services. Whole blood injection models, considered a gold standard, mimic acute hematoma accumulation with precise volume control and are applied in both small animals like rats and mice, and large animals including pigs and sheep. Collagenase models induce localized hemorrhage through microvascular rupture, offering flexibility in hematoma size control through dosage adjustment. Microballoon insertion models simulate the space-occupying effects of ICH, replicating increased intracranial pressure and reduced cerebral blood flow—critical factors in acute brain injury.
The company collaborates with researchers to select optimal models based on study goals, whether focusing on acute versus chronic hematoma phases, molecular versus hemodynamic analysis, or efficacy testing of novel therapeutics. This tailored approach aims to maximize translational value, bridging the gap between preclinical research and clinical application. The comprehensive model portfolio and customization flexibility position Ace Therapeutics as a partner for biotech companies, pharmaceutical firms, and academic researchers dedicated to advancing ICH therapeutics.
By providing researchers with tools that accurately replicate disease mechanisms, Ace Therapeutics' models could accelerate the development of interventions targeting hematoma expansion, secondary injury pathways, and other critical aspects of ICH. This advancement matters because hemorrhagic stroke remains a leading cause of disability and death worldwide, with limited treatment options currently available. The company's specialized models may help overcome preclinical barriers, potentially reducing the time and cost associated with bringing new therapies to patients suffering from this devastating condition.
